Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

LAD603

Phase 2Small molecule

AAlmirall, S.A.

LAD603 is one of 38 small molecule programs targeting Alopecia Areata. It is currently in Phase 2.

1

Indications

2

Total Trials

1

Active Trials

37

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alopecia AreataActive, not recruiting

Alopecia AreataPhase 2

Active, not recruiting

Competition

Competitive Landscape

113 competitors in Alopecia Areata

#DrugCompanyPhaseTrials

Opzelura

Olumiant

Rinvoq

PF-06651600

Orencia

Bristol-Myers Squibb

Jaktinib

SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

Jakafi

Cosentyx

Velsipity

SHR0302

RReistone Biopharma Company Limited

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Alopecia Areata

NCT07311564

Clinical

Trials by Indication[1]

Alopecia Areata1 trial

A Study of LAD603 in Adults With Alopecia Areata

Recruiting·AAlmirall, S.A.·Phase 2·NCT07311564·136 enrolled

Unspecified1 trial

A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects

Completed·AAlmirall, S.A.·Phase 1·NCT06200597·92 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for LAD603. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LAD603 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LAD603. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Almirall, S.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAlmirall, S.A.

Related News